Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Rheumatology
•
Hematology
•
General Rheumatology
•
Infectious Disease
•
Gastroenterology
•
Vaccines
•
immunizations
•
Allergy & Immunology
•
Nephrology
•
Immunosuppression
•
Cardiology
What is your approach to RSV vaccination in immunocompromised patients?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
For patients with VEXAS syndrome and good response to azacitidine, what duration of therapy do you consider?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Does hepatitis B vaccination reduce the risk of HBV reactivation associated with immunosuppressive therapy?